Valneva (VLA) investor relations material

Executive summary

• Total revenues reached €174.7 million in 2025, up from €169.6 million in 2024, with product sales of €157.9 million and a strong year-end cash position of €109.7 million, supported by successful debt refinancing and reduced operating cash burn.

• Proprietary product sales grew 9% at constant exchange rates, while third-party sales declined 42.3% as planned.

• Net loss was €115.2 million, compared to a €12.2 million loss in 2024, with the prior year benefiting from a €90.8 million gain from a Priority Review Voucher sale.

• Operating cash burn improved to €52.9 million in 2025, down from €67.2 million in 2024, reflecting disciplined cost management.

• 2026 is expected to be transformational, with Phase 3 Lyme disease vaccine data anticipated in H1 2026 and regulatory submissions planned.

Financial highlights

• Product sales were €157.9 million, down 3.3% year-over-year, mainly due to planned reduction in third-party sales and adverse FX changes; proprietary product sales grew 9% at constant exchange rates.

• IXIAROⓇ/JESPECTⓇ sales rose 4.6% to €98.4 million; DUKORAL® sales were €31.9 million, slightly down due to currency effects and distribution transition; IXCHIQⓇ sales more than doubled to €8.4 million.

• Gross margin on commercial product sales (excluding IXCHIQⓇ) was 50.8%, with IXIAROⓇ at 59.6%, DUKORAL® at 33.3%, and IXCHIQⓇ negative due to inventory write-offs.

• Adjusted EBITDA loss was €59.4 million in 2025, compared to a €32.9 million profit in 2024, reflecting the absence of the PRV gain.

• Cash and cash equivalents stood at €109.7 million at year-end, down from €168.3 million in 2024.

Outlook and guidance

• 2026 revenue guidance is €155–170 million, with product sales expected between €145–160 million, reflecting continued growth in core brands and further wind-down of third-party sales.

• First Phase 3 data for the Lyme disease vaccine candidate (VLA15) expected in H1 2026, with regulatory submissions to follow if positive.

• First Phase 2 data for the Shigella vaccine candidate (S4V2) expected mid-2026.

• Operating cash burn is expected to decline further in 2026, with continued investment in R&D.

• Sustained profitability targeted from 2027, contingent on successful Lyme disease vaccine approval and commercialization.